Skip to main content

Table 1 Characteristics of randomized controlled trials included in the NMA

From: Comparative efficacy and safety of adjuvant nivolumab versus other treatments in adults with resected melanoma: a systematic literature review and network meta-analysis

Trial Primary publication ClinicalTrials.gov identifier Treatment 1 Treatment 2 Treatment 3 Blinding Phase Multicenter Region
Trials included in final NMAs
ECOG 1697 [22] Agarwala et al. (2017) NCT00003641 IFN alfa-2b (high-dose) Observation NA Open-label III Yes Australia, Canada, South Africa, USA
Scottish study [23] Cameron et al. (2001) NA IFN alfa-2b (low-dose) Observation NA Open-label NR Yes Scotland
WHO Melanoma Programme Trial 16 [24] Cascinelli et al. (2001) NA IFN alfa-2b (low-dose) Observation NA Open-label NR Yes Italy
EORTC 18071 [25] Eggermont et al. (2015) NCT00636168 Ipilimumab Placebo NA Double-blind III Yes Australia, Austria, Belgium, Canada, Czech Republic, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Poland, Russia, Spain, Sweden, Switzerland, United Kingdom, USA
EORTC 18952 [26] Eggermont et al. (2005) NA IFN alfa-2b (high-dose/ 13 months) IFN alfa-2b (low-dose/ 25 months) Observation Open-label III Yes Austria, Belgium, Bulgaria, Croatia, Estonia, Finland, France, Germany, Hungary, Israel, Italy, Poland, Portugal, Russia, Serbia and Montenegro, Slovakia, Spain, Sweden, Switzerland, Netherlands, Turkey, United Kingdom
EORTC 18991 [27] Eggermont et al. (2008) NCT00006249 PEG IFN alfa-2b Observation NA Open-label III Yes Australia, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, France, Germany, Israel, Italy, Netherlands, Poland, Portugal, Slovenia, Spain, Switzerland, Turkey, United Kingdom
KEYNOTE-054 [28, 29] Eggermont et al. (2018) NCT02362594 Pembrolizumab Placebo NA Double-blind III Yes Australia, Belgium, Canada, Denmark, Finland, France, Germany, Israel, Italy, Japan, Netherlands, New Zealand, Norway, Poland, Portugal, Russian Federation, Serbia, Spain, Sweden, Switzerland, United Kingdom, USA
S0008 [30] Flaherty et al. (2014) NCT00006237 IFN alfa-2b (high-dose) Other chemotherapy NA Open-label III Yes Australia, USA
Garbe 2008 (DeCOG) [31] Garbe et al. (2008) NA IFN alfa-2a (low-dose) IFN alfa-2a + dacarbazine Observation Open-label III Yes Germany, Switzerland
AIM HIGH Study [32] Hancock et al. (2004) NA IFN alfa-2a (low-dose) Observation NA Open-label III Yes United Kingdom
Nordic IFN Trial [33] Hansson et al. (2011) NCT01259934 IFN alfa-2b (1 year) IFN alfa-2b (2 years) Observation Open-label III Yes Denmark, Finland, Norway, Sweden
Kim et al. 2009 [34] – NA Cisplatin, vinblastine, dacarbazine, IFN alfa-2b, interleukin-2 IFN alfa-2b (high-dose) IFN alfa-2b (low-dose) Open-label III NR USA
ECOG 1690 [35] Kirkwood et al. (2000) NA IFN alfa-2b (low-dose) IFN alfa-2b (high-dose) Observation Open-label III Yes USA
ECOG 1684 [10] Kirkwood et al. (1996) NA IFN alfa-2b (high-dose) Observation NA Open-label III Yes USA
EORTC 18871 [36] Kleeberg et al. (2004) NA rIFN alfa-2b Observation NA Open-label III Yes Austria, Belgium, Czech Republic, Estonia, France, Germany, Great Britain, Greece, Israel, Poland, Spain, Switzerland, Yugoslavia
COMBI-AD [7, 37] Long et al. (2017) NCT01682083 Dabrafenib + trametinib Placebo NA Double-blind III Yes Argentina, Australia, Austria, Belgium, Brazil, Canada, Czech Republic, Denmark, France, Germany, Greece, Israel, Italy, Japan, Netherlands, New Zealand, Norway, Poland, Russia, Spain, Sweden, Switzerland, Taiwan, United Kingdom, USA
Stadler et al. (2006) [38] – NA Dacarbazine + natural human IFN alfa Observation NA Open-label NR Yes Germany
E1609 [39] Tarhini et al. (2017) NCT01274338 Ipilimumab (high-dose) Ipilimumab (low-dose) IFN alfa-2b (high-dose) Open-label III Yes Canada, USA
CheckMate 238 [15, 40] Weber et al. (2017) NA Nivolumab Ipilimumab NA Double-blind III Yes Argentina, Australia, Austria, Belgium, Canada, Czech Republic, Finland, France, Greece, Hungary, Ireland, Israel, Italy, Japan, Korea, Netherlands, Norway, Poland, Romania, South Africa, Spain, Sweden, Switzerland, Taiwan, United Kingdom, USA
Trials excluded from final NMAs
Eigentler et al. 2016 (DeCOG) [41] Eigentler et al. (2016) NCT00204529 PEG IFN alfa-2a IFN alfa-2a (low-dose) NA Open-label III Yes Austria, Germany
EADO study [42] Grob et al. (2013) NCT00221702 PEG IFN alfa-2b IFN alfa-2b (low-dose) NA Open-label III Yes Austria, France, Germany
Lian et al. (2013) [43] – NA IFN alfa-2b (high-dose) Chemotherapy Observation NR II No China
Sunbelt Melanoma Trial [44] McMasters et al. (2016) NA IFN alfa-2b (high-dose) Observation NA Open-label III Yes Canada, USA
MM-ADJ-5 [45] Mohr et al. (2015) NCT00226408 IFN alfa-2b (high-dose) IFN alfa-2b (intermittent high-dose) NA Open-label III Yes Austria, Germany, Greece, Switzerland
Tobin et al. (2018) [46] – NCT02403778 Ipilimumab Ipilimumab plus ATRA NA Open-label II No USA
Wang et al. (2015) [47] – NA IFN alfa-2b (high-dose) Observation NA Open-label II No China
  1. ATRA all-trans retinoic acid, IFN interferon, NA not applicable, NMA network meta-analysis, NR not reported, PEG pegylated, rIFN recombinant IFN
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us